Related Experiment Video
Updated: Jul 4, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Primary pulmonary choriocarcinoma: a case report.
Gyorgy L Vegh1, Ivan Szigetvári, Ibolya Soltesz
1Department of Obstetrics and Gynecology, National Medical Center, Budapest, Hungary. glvegh@ogyik.hu
The Journal of Reproductive Medicine
|June 24, 2008
Summary
Primary pulmonary choriocarcinoma, a rare lung cancer, can be successfully treated with surgery and chemotherapy. Monitoring human chorionic gonadotropin (hCG) levels is crucial for tracking remission in these rare tumors.
Area of Science:
- Oncology
- Pulmonary Medicine
- Rare Cancers
Background:
- Primary pulmonary choriocarcinoma (PPC) is exceptionally rare.
- Unlike gestational trophoblastic tumors, extragonadal choriocarcinomas often resist treatment and have a poor prognosis.
- The distinct behavior of non-gestational choriocarcinomas compared to gestational tumors remains unexplained.
Observation:
- A case report details a 30-year-old female patient diagnosed with primary choriocarcinoma of the lung.
- The patient underwent successful treatment involving surgical resection and multiple cycles of combination chemotherapy.
- Recovery was monitored via human chorionic gonadotropin (hCG) titer measurements.
Findings:
- Complete remission of the disease was achieved after 1 year of close surveillance of beta-hCG levels.
- Surgical resection is the primary treatment modality for PPC.
- Postoperative chemotherapy is recommended immediately, as beta-hCG serves as a reliable tumor marker, obviating the need for definitive histologic confirmation before treatment initiation.
Implications:
- Establishes a potential treatment protocol for the rare condition of primary pulmonary choriocarcinoma.
- Highlights the importance of beta-hCG monitoring as a diagnostic and prognostic tool.
- Suggests that prompt chemotherapy post-surgery can lead to successful outcomes in PPC.